TY - JOUR
T1 - Rivastigmine for Refractory REM Behavior Disorder in Mild Cognitive Impairment.
AU - Della Marca, Giacomo
PY - 2014
Y1 - 2014
N2 - Background: Mild Cognitive Impairment (MCI) and REM Behavior Disorder (RBD) are both associated with a degeneration of ponto-medullary cholinergic pathways. Methods: We conducted a placebo-controlled, cross-over pilot trial of Rivastigmine (RVT) in 25 consecutive patients with MCI, who presented RBD refractory to conventional first-line treatments (melatonin up to 5 mg/day and clonazepam up to 2 mg/day). Results: RVT treatment was followed by a significant reduction of RBD episodes when compared with placebo. Conclusions: Our data suggest that, in MCI patients with RBD resistant to conventional therapies (muscle relaxants benzodiazepines or melatonin,) treatment with RVT may induce a reduction in the frequency of RBD episodes compared to placebo.
AB - Background: Mild Cognitive Impairment (MCI) and REM Behavior Disorder (RBD) are both associated with a degeneration of ponto-medullary cholinergic pathways. Methods: We conducted a placebo-controlled, cross-over pilot trial of Rivastigmine (RVT) in 25 consecutive patients with MCI, who presented RBD refractory to conventional first-line treatments (melatonin up to 5 mg/day and clonazepam up to 2 mg/day). Results: RVT treatment was followed by a significant reduction of RBD episodes when compared with placebo. Conclusions: Our data suggest that, in MCI patients with RBD resistant to conventional therapies (muscle relaxants benzodiazepines or melatonin,) treatment with RVT may induce a reduction in the frequency of RBD episodes compared to placebo.
KW - REM Behavior disorder
KW - Rivastigmine
KW - REM Behavior disorder
KW - Rivastigmine
UR - http://hdl.handle.net/10807/56886
U2 - 10.2174/1567205011666140302195648
DO - 10.2174/1567205011666140302195648
M3 - Article
SN - 1567-2050
SP - 267
EP - 273
JO - Current Alzheimer Research
JF - Current Alzheimer Research
ER -